



Medtech Evolution Restrictions of BPACNZRx (BPACNZRx) Integration User Guide

Version: 4.0
Release Date: July 2021

CONTENTS

- Restrictions of the BPACNZRx solution3
 - Pregnancy warnings are displayed regardless of age 3
 - No ability to suppress drugs 'at risk when pregnant' 3
 - Extension of Medical Warnings to allow 'Other Substance' allergies to be recorded 3
 - No cross-sensitivity checks 4
 - Price may be incorrectly displayed 4
 - Activation of BPACNZRx is at Database Level not Practice Level 4

Restrictions of the BPACNZRx solution

There are several restrictions that should be understood with regards to the use of the BPACNZRx integrated New Zealand Formulary data within Medtech Evolution:

Pregnancy warnings are displayed regardless of age

Pregnancy monograph information displays for all patients regardless of their age or gender (This is important as some medications may affect male fertility) in this release of BPACNZRx. BPACNZRx may introduce user-controlled settings in future releases to allow a provider to set the age boundaries for presenting the pregnancy warnings.

No ability to suppress drugs 'at risk when pregnant'

The approach of using pregnancy risk categories has several limitations, including that:

- It does not provide information about risks across different trimesters of pregnancy
- Medicines with a wide range of associated risks could be included in the same category
- The categories imply a grading system, which could lead to prescribing based on the risk category rather than an understanding of the evidence of risks and benefits for a particular patient
- The single-letter classification system does not provide enough information to support informed decision making by prescribers and patients

As a result of these shortcomings, there is an international movement away from using pregnancy safety categories, and in their place providing descriptions, where applicable, of the underlying evidence, degree of severity, timing of effects on the developing foetus and areas where there is a lack of evidence.

BPACNZRx includes brief advice on the safety of medicines in pregnancy and lactation from the textbook 'Drugs in Pregnancy and Lactation 2017' (used by permission from Wolters Kluwer Health). This information is available in an expandable section in a medicine monograph.

Extension of Medical Warnings to allow 'Other Substance' allergies to be recorded

Substances which are contained within medications can be located within the Generic Name category such as peanuts/arachis oil, egg, soy oil & almond oil etc.

However, non-medicinal substance allergies can also be recorded within Other Substances such as Cow's milk, Fish & pollen etc.

Recording of these allergies may reveal relationships between medication & other substance allergies.

No cross-sensitivity checks

Alerting groups do not provide cross-reactivity drug checks in this release of BPACNZRx. BPACNZRx is reviewing the group structure and may add these checks in future releases.

Price may be incorrectly displayed

If prescribers identify any incorrect pricing information, they are encouraged to report this to the NZ Formulary via their feedback page <https://nzf.org.nz/Feedback> , however prices for non-subsidised products should not be relied on due to the difficulty in maintaining up to date pricing.

Activation of BPACNZRx is at Database Level not Practice Level

If your practice shares a database with other practices, all practices will be activated when switching to BPACNZRx.